Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif, Fudan University, China

Dr. Mohammed Ahmed Akkaif is a Postdoctoral Researcher in the Department of Cardiology at Fudan University, China. He earned his Ph.D. in Clinical Pharmacy from Universiti Sains Malaysia in 2023, specializing in precision medicine, pharmacogenetics, and cardiology. A Young Ambassador for the European Association of Preventive Cardiology (2022–2024), he has published 34 peer-reviewed articles, with 29 indexed in SCI, and has over 2,179 citations. Recognized with the Young Researchers Award (ESC Asia 2022), he is a reviewer for 50+ high-impact journals. His research focuses on optimizing antithrombotic drug therapies through pharmacometabolomics for personalized cardiovascular treatment.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Mohammed Ahmed Akkaif began his academic journey with a strong foundation in Clinical Pharmacy at Universiti Sains Malaysia, where he completed his Doctor of Philosophy (PhD) in July 2023. During his PhD, he focused on the intersection of clinical pharmacy and biotechnology, gaining expertise in personalized and precision medicine. His academic accomplishments included publishing 10 articles (8 in SCI Q1 and Q2 journals) and presenting at six international conferences. This period also saw him design innovative approaches to enhance antithrombotic drug treatment, particularly through CYP2C19 genotype-guided antiplatelet therapy.

💼PROFESSIONAL ENDEAVORS:

Currently, Dr. Akkaif serves as a Postdoctoral Researcher in the Department of Cardiology at Fudan University’s Qingpu Branch of Zhongshan Hospital, China. His role involves leading advanced research in cardiovascular medicine, with a specialized focus on the clinical application of personalized medicine in cardiology. Additionally, he has served as a Young Ambassador for the European Association of Preventive Cardiology (EAPC) from 2022 to 2024, demonstrating his commitment to advancing heart health on a global scale. He has also contributed his expertise to several prestigious journals, with over 50 reviews in high-impact journals such as Journal of the American Heart Association and Arteriosclerosis, Thrombosis, and Vascular Biology.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR PHARMACOLOGY:

Dr. Akkaif’s research is primarily focused on pharmacogenetics and pharmacometabolomics, with a goal of improving personalized treatment strategies in cardiology. His work delves into the optimization of antithrombotic drug therapies through genetic and metabolic profiling, which holds the potential to revolutionize treatment protocols, making them more tailored to individual patient profiles. His research also bridges the gap between clinical pharmacy and biotechnology, aiming to develop more effective, individualized approaches to cardiovascular health.

🌍IMPACT AND INFLUENCE:

Dr. Akkaif’s contributions have already made a significant impact on both academic research and the practical application of precision medicine. He has been honored with the Young Researchers Award at the 2022 ESC Asia Conference in Singapore, highlighting his early recognition in the field. His research has also led to the publication of 34 peer-reviewed articles, with 29 of them indexed in SCI (Clarivate), reflecting his growing influence in the field of cardiovascular pharmacology. His work has contributed to advancing the understanding of genetic factors in drug response, and his findings are regularly cited by researchers and clinicians alike.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Akkaif’s publications have earned him considerable academic recognition, with a cumulative citation count of 2,179 as of now. This citation count reflects the profound influence his work has had on the scientific community, particularly in the areas of pharmacogenetics, pharmacometabolomics, and cardiology. His ability to produce impactful, high-quality research is evident through his consistent presence in top-tier journals, where his findings continue to shape the discourse on personalized medicine.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

As Dr. Akkaif continues his postdoctoral work at Fudan University, his future contributions are poised to expand on his research in precision medicine and cardiology. Given his accomplishments thus far, his research promises to lead to more personalized treatment options for cardiovascular diseases, potentially transforming clinical practices and improving patient outcomes globally. His ongoing efforts in understanding the genetic and metabolic factors influencing drug efficacy will likely place him at the forefront of the personalized medicine movement, paving the way for future innovations in the medical field.

🏆KEY AWARDS AND HONORS:

  • Young Researchers Award at the 2022 ESC Asia Conference (Singapore)

  • Second Prize for the Young Investigator Award at the ESC Asia Congress in Singapore 2022

  • Young Ambassador of the European Association of Preventive Cardiology (EAPC) (2022–2024)

  • Reviewing Excellence for over 50 high-impact SCI Q1 and Q2 journals

🌍CONCLUSION:

Dr. Mohammed Ahmed Akkaif’s groundbreaking research in precision medicine and cardiology continues to shape the future of personalized healthcare. With a strong academic background, numerous publications, and recognition through prestigious awards, his work is making significant contributions to improving cardiovascular treatments. His role as a Young Ambassador for the European Association of Preventive Cardiology further highlights his dedication to global health. As he advances his postdoctoral research at Fudan University, Dr. Akkaif’s future endeavors hold the potential to revolutionize clinical practices, particularly in pharmacogenetics and pharmacometabolomics, ensuring more effective and individualized patient care.

TOP NOTABLE PUBLICATIONS:

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in …

Authors: AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, …

Journal: The Lancet

Year: 2024

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease …

Authors: M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, …

Journal: The Lancet

Year: 2024

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the …

Authors: The Lancet

Year: 2024

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Authors: M Naghavi, SE Vollset, KS Ikuta, LR Swetschinski, AP Gray, EE Wool, …

Journal: The Lancet

Year: 2024

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Authors: SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Authors: VL Feigin, MD Abate, YH Abate, S Abd ElHafeez, F Abd-Allah, …

Journal: The Lancet Neurology

Year: 2024

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Authors: NV Bhattacharjee, AE Schumacher, A Aali, YH Abate, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

Authors: MA Akkaif, NAA Daud, A Sha’aban, ML Ng, MAS Abdul Kader, DA Noor

Journal: Molecules

Year: 2021

A review of the effects of ticagrelor on adenosine concentration and its clinical significance

Authors: MA Akkaif, ML Ng, MASA Kader, NAA Daud, A Sha’aban, B Ibrahim

Journal: Pharmacological Reports

Year: 2021

National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050

Authors: M Ng, X Dai, RM Cogen, M Abdelmasseh, A Abdollahi, A Abdullahi, …

Journal: The Lancet

Year: 2024

 

Zhihui Zhang | Cardiovascular Research | Best Researcher Award

Prof. Zhihui Zhang | Cardiovascular Research | Best Researcher Award

Prof. Zhihui Zhang, Army Medical University, China

Prof. Zhihui Zhang is a distinguished researcher at Army Medical University, China, specializing in cardiovascular diseases and stem cell therapy. His work focuses on endothelial seed cells, myocardial infarction, and immunosuppressive capabilities of mesenchymal stem cell-derived extracellular vesicles. He has published extensively in leading journals such as Genes and Diseases, Science Bulletin, and Stem Cell Research and Therapy. Prof. Zhang’s research contributes to advancing early diagnosis and targeted interventions for coronary microvascular dysfunction. His expertise in molecular biology and regenerative medicine has made significant impacts in cardiovascular research and clinical applications.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Zhihui Zhang embarked on his academic journey with a deep passion for cardiovascular medicine. His early education laid a strong foundation in medical sciences, leading him to specialize in cardiology. His dedication and excellence in research and clinical practice positioned him for advanced studies and significant contributions to the field.

🏥PROFESSIONAL ENDEAVORS:

Dr. Zhang is the Director of the Department of Cardiology at the First Affiliated Hospital (Southwest Hospital) of the Army Medical University in Chongqing. His leadership extends beyond the hospital as he holds multiple prestigious roles:

  • Member of the Great Vessel Group under the Cardiology Branch of the Chinese Medical Association
  • Member of the Cardiologists’ Association of the Chinese Medical Doctor Association
  • Deputy Director of the Committee for Structural Heart Disease under the China Human Health Promotion Association
  • Deputy Director of the Cardiology Branch of the Chongqing Medical Association, leading the Interventional Cardiology and Imaging Group

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCH:

Dr. Zhang is renowned for his expertise in interventional treatment of coronary heart disease and structural heart disease. His research focuses on:

  • Precise diagnosis and treatment of coronary heart disease
  • Interventional therapy for valvular heart diseases
  • Establishing a cohort for precise classification of myocardial ischemia
  • Creating a biobank and an artificial intelligence center for coronary angiography physiological assessment

Additionally, he has developed the professional Circa Met DB database, specializing in metabolic circadian rhythms.

🌍IMPACT AND INFLUENCE:

Dr. Zhang’s contributions have earned him numerous accolades, including:
🏆 Two first prizes for scientific progress in Chongqing
🏆 One first prize for scientific progress in Hubei Province
🏆 One second prize for military medical achievements

He has successfully led over 20 research projects, ranging from national natural science funds to key military and Chongqing talent programs. His pioneering work in cardiology has influenced national and military healthcare policies.

📖ACADEMIC CITATIONS:

Dr. Zhang has an outstanding publication record, with more than 30 SCI papers as the first or corresponding author (including co-first/co-corresponding). His research has been featured in top-tier journals such as:
📌 The Lancet
📌 Nature Metabolism
📌 Nature Communications
📌 Trends in Cell Biology

Additionally, he has contributed to drafting and setting 12 expert consensus documents, served as a deputy editor for two monographs, and contributed to nine other books. His work extends to two national invention patents, further solidifying his impact in the field.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

As a recipient of the Outstanding Youth Talent Fund in National Defense Bioscience, Dr. Zhang is recognized as a key innovator in cardiology. He has been honored as an Innovation Leading Talent by the Chongqing Talents Program and as a Science and Technology Talent by the Army.

His legacy will continue to shape the future of cardiovascular medicine through:
Advanced research in interventional cardiology
Expansion of AI-driven medical diagnostics
Development of groundbreaking therapeutic techniques
Mentorship and training of future cardiologists

🌟CONCLUSION:

Prof. Zhihui Zhang is a visionary leader in cardiology, blending clinical excellence, groundbreaking research, and technological innovation. His contributions have not only transformed patient care but also advanced global medical knowledge. His work will undoubtedly influence generations of medical professionals and redefine the future of cardiovascular treatment.

TOP NOTABLE PUBLICATIONS

Single nucleotide polymorphisms: Implications in the early diagnosis and targeted intervention of coronary microvascular dysfunction

Authors: Dingyuan Tian, Jie Li, Qingyuan Yang, Zhihui Zhang, Fang Deng

Journal: Genes and Diseases

Year: 2025

Circadian nutrition: is meal timing an elixir for fatigue?

Authors: Zhihui Zhang, Lu Yan, Jonas T. Treebak, Min-Dian Li

Journal: Science Bulletin

Year: 2025

Foxo1 drives the TGFβ1-dependent dichotomy of Th17 cell fates

Authors: Mengjuan Zhang, Yude Guan, Meijuan Han, Xiaomin Zhang, Song Zhang

Journal: Journal of Leukocyte Biology

Year: 2025

The short-term outcomes and risk factors of post-myocardial infarction ventricular septal rupture: a multi-center retrospective study

Authors: Wenjian Luo, Li Wen, Jinning Zhang, Zhexue Qin, Shiyong Yu

Journal: Journal of Cardiothoracic Surgery

Year: 2024

Sources and applications of endothelial seed cells: a review

Authors: Dan Deng, Yu Zhang, Bo Tang, Zhihui Zhang

Journal: Stem Cell Research and Therapy

Year: 2024

Enhanced immunosuppressive capability of mesenchymal stem cell-derived small extracellular vesicles with high expression of CD73 in experimental autoimmune uveitis

Authors: Yanan Duan, Xiteng Chen, Hui Shao, Jiawei Wang, Xiaomin Zhang

Journal: Stem Cell Research and Therapy

Year: 2024

Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression

Authors: Junjie Tang, Yaoming Liu, Yinghao Wang, Ping Zhang, Rong Lu

Journal: Biomarker Research

Year: 2024

Associations between non-insulin-based insulin resistance indices and heart failure prevalence in overweight/obesity adults without diabetes mellitus: evidence from the NHANES 2001–2018

Authors: Diyu Cui, Chao Zhang, Yi Chen, Yu Zhang, Ping Zhu

Journal: Lipids in Health and Disease

Year: 2024

Single-cell transcriptomics enable the characterization of local extension in retinoblastoma

Authors: Yaoming Liu, Wei Hu, Yanjie Xie, Shengli Li, Rong Lu

Journal: Communications Biology

Year: 2024

Clinical characteristics of patients with moderate or severe valvular heart disease

Authors: Hao Gao, Yuzhu Lei, Haiyun Huang, Yanxiu Chen, Zhihui Zhang

Journal: Chinese Journal of Cardiology

Year: 2024

Yingqiang Du | Myocardial Infarction | Best Researcher Award

Dr. Yingqiang Du | Myocardial Infarction | Best Researcher Award

Dr. Yingqiang Du, Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University; Suzhou Municipal Hospital; Gusu School, Nanjing Medical University, China

Dr. Yingqiang Du is a renowned cardiology researcher at The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, and Gusu School, Nanjing Medical University, China. His research focuses on myocardial infarction and ischemic heart disease, exploring inflammation, fibrosis, metabolic remodeling, and novel therapeutic strategies. As the first or corresponding author of multiple high-impact publications, he has significantly contributed to cardiovascular medicine. His work bridges basic and clinical research, influencing treatment advancements and patient care. With ongoing projects funded by prestigious grants, Dr. Du continues to drive innovation in cardiology, shaping the future of cardiovascular health research.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

📚 EARLY ACADEMIC PURSUITS:

Dr. Yingqiang Du began his academic journey with a strong foundation in medical sciences, focusing on cardiology and cardiovascular research. His early education provided him with a deep understanding of human physiology, pathology, and the complexities of ischemic heart disease. With a keen interest in myocardial infarction and its underlying mechanisms, he pursued specialized training and research, laying the groundwork for his future contributions to the field.

🏥 PROFESSIONAL ENDEAVORS:

Currently, Dr. Du is affiliated with The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, and Gusu School, Nanjing Medical University. As a researcher and academic professional, he has taken on significant responsibilities in both clinical and experimental cardiology. His work bridges the gap between theoretical research and practical applications, ensuring that scientific findings translate into improved patient care.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Dr. Du’s research primarily centers on myocardial infarction and ischemic heart disease. His studies delve into various aspects, including:

  • The role of inflammation and fibrosis in cardiovascular conditions.
  • The impact of environmental factors, such as micro(nano)plastics, on heart disease.
  • Novel therapeutic approaches involving bioactive compounds like resveratrol and muscone.
  • The involvement of metabolic remodeling and inflammasome activation in aging cells. His extensive work provides crucial insights into the prevention, diagnosis, and treatment of cardiac disorders.

🌟 IMPACT AND INFLUENCE:

Dr. Du’s research has had a profound impact on the field of cardiology. His studies have contributed to a better understanding of the molecular mechanisms of myocardial infarction and fibrosis, paving the way for new treatment modalities. His findings have influenced clinical practices and have been referenced in various medical and scientific discussions worldwide.

📖 ACADEMIC CITES:

As an established researcher, Dr. Du has authored multiple high-impact publications in reputed journals, including:

  • Journal of Hazardous Materials
  • Clinical and Translational Medicine
  • Experimental and Therapeutic Medicine
  • Bioengineered
  • American Journal of Translational Research These publications, where he serves as either the first or corresponding author, reflect his credibility and expertise in the field. His work has been widely cited by peers, demonstrating its relevance and significance.

🏆 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Du’s contributions to cardiology are paving the way for future breakthroughs in cardiovascular medicine. His research findings are not only enhancing current medical knowledge but also inspiring upcoming researchers to explore novel therapeutic strategies. Moving forward, his work is expected to contribute significantly to:

  • The development of innovative drug treatments for myocardial infarction.
  • The formulation of preventive measures against ischemic heart disease.
  • The exploration of new molecular pathways for better cardiovascular health. His ongoing commitment to research excellence ensures that his legacy will continue to shape the future of cardiology.

🌍CONCLUSION:

Dr. Yingqiang Du is a distinguished researcher whose groundbreaking contributions to cardiology have significantly advanced the understanding of myocardial infarction and ischemic heart disease. His extensive studies on inflammation, fibrosis, and metabolic remodeling have influenced both clinical practices and future research directions. With multiple high-impact publications and ongoing projects, his work continues to shape modern cardiovascular medicine.

TOP NOTABLE PUBLICATION

Title:  Exposure to polyethylene terephthalate micro(nano)plastics exacerbates inflammation and fibrosis after myocardial infarction by reprogramming the gut and lung microbiota and metabolome

Authors: X., Gu, Xin, Z., Zhang, Zhixuan, L., Zhao, Lin, X., Wang, Xiaoyan, Y., Du, Yingqiang

Journal:  Journal of Hazardous Materials

Year: 2025

Quan Yuan | Cardiovascular| Best Researcher Award

Prof. Quan Yuan | Cardiovascular | Best Researcher Award 

Prof. QuanYuan, Wuhan University, China

Professor Quan Yuan, a distinguished researcher at Wuhan University, specializes in analytical chemistry with a focus on developing innovative methods for complex sample analysis. His pioneering work includes creating high-sensitivity field-effect transistor-based biosensors for the detection of myocardial injury biomarkers, significantly advancing rapid and accurate heart disease diagnosis. With over 139 journal publications, an H-Index of 41, more than 6,070 citations, 9 patents, and 2 authored books, Professor Yuan’s contributions are widely recognized. As Deputy Editor of “Sensors & Diagnostics” and a key member of multiple professional committees, he exemplifies excellence in research, leadership, and scientific innovation.

Author Profile

Orcid Profile

Education:

Professor Quan Yuan has an outstanding educational background that has shaped his career in analytical chemistry and biosensor technology. He earned his undergraduate degree in Chemistry from a prestigious institution in China, where he developed a strong foundation in chemical principles and experimental techniques. He pursued his master’s degree, specializing in analytical methods, which laid the groundwork for his innovative research. Professor Yuan completed his Ph.D. in Analytical Chemistry, focusing on advanced biosensor development for medical applications. His academic journey reflects a commitment to excellence, equipping him with the expertise to contribute significantly to science, innovation, and education.

Professional Experience:

Professor Quan Yuan has extensive professional experience in both academia and industry. He has led multiple research projects, including the development of highly sensitive biosensors for myocardial injury biomarkers, which have advanced clinical diagnostic methods. As a Deputy Editor for prominent journals such as Sensors & Diagnostics and Chinese Journal of Chemistry, he actively contributes to the scientific community. Professor Yuan has collaborated on various consultancy projects and has worked with leading organizations to translate his research into practical applications. His contributions span across over 6,000 citations and numerous patents, solidifying his reputation as a leading figure in his field.

Research skills:

Professor Quan Yuan possesses exceptional research skills in analytical chemistry and biosensor development. His expertise lies in designing high-sensitivity detection methods, particularly for complex samples such as body fluids and tissues. He has developed a field-effect transistor-based biosensor capable of detecting multiple myocardial injury biomarkers, using advanced machine learning algorithms for risk assessment and prognosis monitoring. His proficiency in integrating circuit technology with biosensors has led to the creation of a portable analysis system for rapid clinical diagnostics. Professor Yuan’s skills in both experimental design and data interpretation, alongside his interdisciplinary approach, have significantly impacted the medical diagnostics field.

Awards and Honors:

Professor Quan Yuan has received numerous awards and honors in recognition of his groundbreaking contributions to analytical chemistry and biomedical diagnostics. His research has earned him significant recognition in the scientific community, including over 6,070 citations and an H-Index of 41. He holds 9 patents and has published extensively in prestigious journals. In addition to his research achievements, Professor Yuan serves as Deputy Editor for “Sensors & Diagnostics” and the “Chinese Journal of Chemistry.” He is actively involved in several professional committees, including the Chinese Chemical Society and the China Medical Equipment Association, showcasing his leadership in advancing scientific innovation.

Conclusion:

Professor Quan Yuan’s exceptional research and groundbreaking innovations in analytical chemistry, particularly in the development of advanced biosensors for heart disease diagnosis, make him a highly deserving candidate for the Best Researcher Award. His pioneering work has not only advanced scientific understanding but also led to practical applications in clinical diagnostics, improving patient care. With a remarkable publication record, numerous patents, and influential roles in editorial and professional committees, Professor Yuan’s leadership in both research and academia has significantly impacted the field. His ongoing contributions continue to shape the future of medical diagnostics and scientific innovation.

Top Notable Publications

Persistent luminescence encoding for rapid and accurate oral-derived bacteria identification

Authors: Not provided

Journal: Chinese Chemical Letters

Year: 2025

Staggered-Stacking Two-Dimensional Covalent Organic Framework Membranes for Molecular and Ionic Sieving

Authors: Not provided

Journal: ACS Nano

Year: 2024

Bio‐Inspired Multiple Responsive NIR II Nanophosphors for Reversible and Environment‐Interactive Information Encryption

Authors: Not provided

Journal: Advanced Materials

Year: 2024

Framework nucleic acid strategy enables closer microbial contact for programming short-range interaction

Authors: Not provided

Journal: Science Advances

Year: 2024

Defect Regulation Strategy of Porous Persistent Phosphors for Multiple and Dynamic Information Encryption

Authors: Not provided

Journal: Small Methods

Year: 2024

DNA Nanomaterial-Based Electrochemical Biosensors for Clinical Diagnosis

Authors: Not provided

Journal: ACS Nano

Year: 2024

Smart Persistent Luminescence Imaging for Early Diagnosis of Drug-Induced Liver Injury

Authors: Not provided

Journal: Chemical & Biomedical Imaging

Year: 2024

Thermodynamics and Kinetics‐Directed Regulation of Nucleic Acid‐Based Molecular Recognition

Authors: Not provided

Journal: Small Methods

Year: 2024

Bionic Potassium Ion Channel in Live Cells Repairs Cardiomyocyte Function

Authors: Not provided

Journal: Journal of the American Chemical Society

Year: 2024

Self‐Powered and Self‐Recoverable Multimodal Force Sensors Based on Trap State and Interfacial Electron Transfer

Authors: Not provided

Journal: Angewandte Chemie International Edition / Angewandte Chemie

Year: 2024